bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.02.17.706273

Fast structural search for classification of gut bacterial mucin O-glycan degrading enzymes

Abstract

The Enzyme Commission (EC) numbering scheme provides a hierarchical way to classify enzymes according to their catalytic functions. While recent protein language model (PLM) based approaches like CLEAN and ProteInter have improved sequence-based EC number prediction, they struggle with fine-grained classification at the deepest hierarchical level. Structure-based approaches for grouping similar proteins using alignment tools excel at finding proteins that share overall global structure, but suffer from high false positive rates when classifying proteins that are globally structurally similar but functional differentiation depends on a localized region. This problem is particularly relevant to EC number prediction, as enzymatic function depends on its catalytic domain, which is a relatively small, specific region of the protein. We introduce Deep Enzyme Function Transfer (DEFT) that harmonizes sequence- and structure-based approaches through the key insight that PLM based annotations of the first two EC number hierarchy levels vastly reduce false positives that are likely to show in purely structure-based EC number prediction. Given an enzyme of interest, DEFT first uses a PLM based method to assign the first two levels of the enzymes EC number, and then uses a structure-based method to predict the remaining two levels of the EC number. Using benchmarking datasets, we demonstrate that DEFT achieves superior accuracy compared with current state-of-the-art tools for EC number prediction. Furthermore we show that DEFTs computational efficiency enables high-throughput, genome-wide annotations of total enzyme repertoires in organisms. We illustrate this capability by experimentally validating DEFT predicted glycoside hydrolase (GH) profiles of intestinal mucus associated bacteria. Author summaryEnzymes are ubiquitous proteins that catalyze chemical reactions of living cells. Enzymes are classified using a hierarchical numbering system called Enzyme Commission (EC) numbers that describe the chemical reactions the enzymes catalyze, from a general reaction type (e.g., breaking bonds, transferring chemical groups, etc.) to more specific aspects such as chemical bonds and substrates involved in the reaction. We present a new machine learning method for predicting EC numbers called Deep Enzyme Function Transfer (DEFT). This method improves on previous methods that use either protein sequence- or three-dimensional (3D) structure-based comparisons between enzymes of known and unknown classification. DEFT combines the strengths of both approaches by first using a protein sequence-based model to predict the general enzyme category and then using protein structure comparisons to predict the finer subcategories. We demonstrate that DEFT achieves superior accuracy compared with current state-of-the-art tools for EC number prediction. We next demonstrate how DEFTs computational efficiency enables us to perform high-throughput, genome-wide annotations of organisms enzyme repertoires. We illustrate this capability by experimentally validating DEFT predicted sugar metabolizing enzyme profiles of intestinal mucus associated bacteria.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Erden, M., Schult, T., Yanagi, K., Sahoo, J. K., Kaplan, D. L., Cowen, L. J., Lee, K.. 2026-02-18. Fast structural search for classification of gut bacterial mucin O-glycan degrading enzymes. https://doi.org/10.64898/2026.02.17.706273

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗